文献速递类风湿关节炎

类风湿关节炎中生物制剂改善病情抗风湿药的持续性:韩国国民健康保险数据库分析

Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database.
PubMed 文献 · Semin Arthritis Rheum · 2017-08-31

本研究基于韩国国民健康保险数据库开展回顾性队列研究,比较阿达木单抗、依那西普、英夫利西单抗或阿巴西普作为类风湿关节炎一线及后续治疗的1年持续性。一线治疗中三种TNF抑制剂持续性相近;后续治疗中依那西普和阿巴西普的停药风险显著低于英夫利西单抗。

要点

  • 一线治疗1年持续性:阿达木单抗52.5%、依那西普56.1%、英夫利西单抗52.6%,无显著差异。
  • 后续治疗1年持续性:阿达木单抗45.7%、依那西普58.5%、英夫利西单抗43.0%、阿巴西普60.4%。
  • 后续治疗中依那西普(HR=0.68)和阿巴西普(HR=0.53)停药风险显著低于英夫利西单抗。

核心结论

  • 阿达木单抗、依那西普和英夫利西单抗作为一线治疗时1年持续性相似。
  • 作为后续治疗时,依那西普和阿巴西普的持续性高于英夫利西单抗或阿达木单抗。
  • 在韩国类风湿关节炎患者中选择后续生物制剂时可考虑持续性因素。

研究设计与样本

  • 回顾性队列研究,使用韩国全国健康保险数据库。
  • 纳入2009年7月1日至2012年12月31日期间接受阿达木单抗、依那西普、英夫利西单抗或阿巴西普治疗的患者。
  • 新开始生物制剂治疗者归为一线使用队列,从其他生物制剂切换者归为后续使用队列。
  • 一线使用队列4114例,后续使用队列992例。

主要发现

  • 一线使用队列中阿达木单抗、依那西普和英夫利西单抗的1年持续性分别为52.5%、56.1%和52.6%,Cox比例风险模型未发现持续性 duration 有显著差异。
  • 后续使用队列中阿达木单抗、依那西普、英夫利西单抗和阿巴西普的1年持续性分别为45.7%、58.5%、43.0%和60.4%。
  • 后续使用队列中,依那西普(HR=0.68,95%CI:0.52-0.88)和阿巴西普(HR=0.53,95%CI:0.37-0.74)的停药风险显著低于英夫利西单抗。

关键数值与推荐

  • 一线使用队列1年持续性:阿达木单抗52.5%,依那西普56.1%,英夫利西单抗52.6%。
  • 后续使用队列1年持续性:阿达木单抗45.7%,依那西普58.5%,英夫利西单抗43.0%,阿巴西普60.4%。
  • 后续使用队列停药风险比较:依那西普 vs 英夫利西单抗 HR=0.68(95%CI:0.52-0.88),阿巴西普 vs 英夫利西单抗 HR=0.53(95%CI:0.37-0.74)。

临床怎么用

  • 一线选择阿达木单抗、依那西普或英夫利西单抗时,1年持续性预期相近。
  • 后续治疗选择依那西普或阿巴西普可能比英夫利西单抗有更高的1年持续性。
  • 持续性可作为后续生物制剂选择的参考因素之一。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study examined and compared the persistence of adalimumab, etanercept, infliximab, or abatacept as first- and subsequent-line treatment for rheumatoid arthritis in the South Korean clinical practice. METHODS: We conducted a retrospective cohort study with patients receiving adalimumab, etanercept, infliximab, or abatacept between July 1, 2009 and December 31, 2012, using the nationwide Korean National Health Insurance database. Patients who were receiving a newly initiated biologic treatment and those who switched from other biologic treatment were identified and classified into first- and subsequent-use cohorts, respectively. Treatment patterns during the 1-year after treatment initiation were measured as persistence, and discontinuation including restarting, switching, and stopping. The Cox proportional hazard model was used to estimate hazard ratios (HRs) and their 95% confidence intervals (CIs) for discontinuation of biologic treatments. RESULTS: We identified 4114 patients for the first-use cohort and 992 patients for the subsequent-use cohort. Treatment persistence with adalimumab, etanercept, and infliximab was observed in 52.5%, 56.1%, and 52.6% of the patients, respectively, in the first-use cohort, without significant differences in duration of persistence among the treatments according to the Cox proportional hazard model. In the subsequent-use cohort, treatment persistence with adalimumab, etanercept, infliximab, and abatacept was observed in 45.7%, 58.5%, 43.0%, and 60.4% of the patients, respectively. The Cox proportional hazard model found that the patients who were receiving etanercept (HR = 0.68, 95% CI: 0.52-0.88) and abatacept (HR = 0.53; 95% CI: 0.37-0.74) were significantly less likely to discontinue the treatment than those who were receiving infliximab. CONCLUSIONS: Adalimumab, etanercept, and infliximab had similar levels of persistence during the 1-year after treatment initiation, when used as first-line treatment. However, when used as a subsequent-line treatment, etanercept and abatacept had higher persistence than infliximab or adalimumab. Persistence could be a consideration when selecting the subsequent-line biologic treatment for patients with rheumatoid arthritis in South Korea.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Lee MY, Shin JY, Park SY, et al. Persistence of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: An analysis of the South Korean National Health Insurance Database. Semin Arthritis Rheum. 2017. PMID: 28939234. doi:10.1016/j.semarthrit.2017.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。